NEW YORK (GenomeWeb) – NeoGenomics today reported an 18 percent year-over-year increase in second quarter revenues, including a 12 percent rise in testing revenue. 

For the three months ended June 30, the Ft. Myers, Florida-based cancer genetics testing company posted $24.3 million in revenues, up from $20.7 million in the year-ago quarter but falling shy of analysts' consensus estimate of $25.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.